Impact of quarantine and face masks on ragweed-induced oculorhinitis during the COVID-19 pandemic in Northern Italy

Marco Dubini MD1 | Carlo Robotti MD2,3 | Marco Benazzo MD2,3 | Federica Rivolta MD4

1 Allergy and Clinical Immunology Residency, University of Milan, Milan, Lombardia, Italy
2 Department of Otolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3 Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy
4 General Medicine, Immunology, and Allergology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

Correspondence
Carlo Robotti, MD, Department of Otorhinolaryngology–Head and Neck Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Viale Camillo Golgi 19, 27100 Pavia, Italy.
Email: carlorobotti@gmail.com

[Correction added on 16 May 2022, after first online publication: CRUI funding statement has been added.]

KEYWORDS
allergy, ambrosia, lockdown, pollen, rhinitis, SARS-CoV-2

INTRODUCTION

Common ragweed (Ambrosia artemisiifolia) represents a growing threat to European sensitive atopic patients. In fact, during the last two decades, the prevalence of this allergy has increased in heavily ragweed colonized areas (Eastern France, Northern Italy), afflicting as much as 12% of the general population.1,2 Furthermore, ragweed pollen-induced symptoms (ocularrhinitis, asthma) significantly impair quality of life (QoL), leading to considerable healthcare costs and relevant economic burdens.3 After the start of the Coronavirus Disease 2019 (COVID-19) pandemic, near-universal face-masking policies were adopted on a global scale. Moreover, social-distancing and work-from-home policies drastically decreased outdoor human activities.4 It is conceivable that these profound changes may have variously affected atopic patients. However, to the best of our knowledge, no study has been conducted so far to specifically assess the impact of anti-COVID-19 measures on ragweed-induced oculorhinitis. Therefore, the present survey study was designed to investigate the effects of quarantine and face-masking policies on nasal and ocular symptoms in a pool of patients suffering from ragweed allergy.

METHODS

Between November 2020 and December 2020, 124 patients (61 males and 63 females, mean age 48.2 years, standard deviation ± 15.9 years, age range 18–72 years) formerly diagnosed with ragweed-related allergic oculorhinitis were consecutively recruited. Specifically, patients undergoing ragweed-specific immunotherapy and COVID-19 patients were excluded. Geographic location (Lombardy, Northern Italy) was verified for each participant. All patients confirmed to have always used face masks (surgical masks or N95 masks) in the outdoors after the declaration of the pandemic by the World Health Organization (March 2020). Clinical-demographic data were collected electronically. For symptom assessment, patients were instructed to answer referring to the symptom diary of the whole...
TABLE 1  Clinical-demographic characteristics of the enrolled 124 participants during the 2019 and the 2020 ragweed seasons in Northern Italy

| Variable                                                                 | 2019       | 2020       | Trend (%)   | p-value |
|--------------------------------------------------------------------------|------------|------------|-------------|---------|
| **Overall self-perceived burden**                                         |            |            |             |         |
| VAS (mean ± SD)                                                          | 5.6 ± 2.1  | 4.3 ± 2.2  | −22.9%      | 0.006   |
| **Nasal symptoms**                                                       |            |            |             |         |
| Sneezing (mean ± SD)                                                     | 3.3 ± 1.4  | 2.0 ± 1.5  | −38.0%      | <0.001  |
| Rhinorrhea (mean ± SD)                                                   | 3.5 ± 1.3  | 2.2 ± 1.6  | −37.4%      | <0.001  |
| Nasal obstruction (mean ± SD)                                            | 3.2 ± 1.4  | 1.9 ± 1.6  | −40.0%      | <0.001  |
| Nasal itching (mean ± SD)                                                | 3.2 ± 1.4  | 1.9 ± 1.5  | −39.3%      | <0.001  |
| **Ocular symptoms**                                                      |            |            |             |         |
| Watering eyes (mean ± SD)                                                | 2.5 ± 1.6  | 2.6 ± 1.6  | +4.2%       | 0.607   |
| Swollen eyes (mean ± SD)                                                 | 2.6 ± 1.7  | 2.7 ± 1.8  | +4.1%       | 0.725   |
| Eye itch (mean ± SD)                                                     | 2.6 ± 1.9  | 2.6 ± 1.7  | −1.4%       | 0.998   |
| Tired or sore eyes (mean ± SD)                                           | 2.6 ± 1.8  | 2.6 ± 1.8  | 0.0%        | 0.963   |
| **Over-the-counter anti-allergic medications (total number of days of therapy)** |            |            |             |         |
| Oral H1 antihistamines (mean ± SD)                                       | 15.1 ± 10.2| 8.6 ± 8.0  | −43.4%      | 0.033   |
| Steroid nasal sprays (mean ± SD)                                         | 12.6 ± 10.4| 7.1 ± 8.3  | −43.2%      | 0.047   |
| H1 Antihistamine Eye Drops (mean ± SD)                                   | 9.6 ± 9.4  | 9.5 ± 9.3  | −0.4%       | 0.906   |

Abbreviations: VAS, Visual Analogue Scale; SD, Standard Deviation.

The Annual Pollen Integral (API) was 120 grains/m³ in 2019 and 84 grains/m³ in 2020 (source: http://www.pollinieallergia.net/bollettino-pollini-riepilogo/2019/lombardia/compositae_ambrosia). During the 2020 ragweed season, the self-reported overall burden of ragweed ocularrhinitis decreased significantly (~22.9%, p = 0.006), and all screened nasal symptoms (sneezing, rhinorrhea, nasal obstruction, nasal itching) improved significantly (p<0.001). Contrariwise, all ocular symptoms (watering eyes, swollen eyes, eye itching, tired or sore eyes) reported no significant variation in comparison with the previous year (p > 0.05). With regards to common anti-allergic medications, a significant reduction in use of oral H1 antihistamines and steroid nasal sprays was found (p < 0.005). Conversely, the use of eye drops resulted unchanged (p = 0.906).

DISCUSSION

Inhaled allergens can trigger IgE-mediated immunological responses in sensitive patients, causing conjunctivitis, and rhinitis. The diameter of ragweed pollen grains usually ranges from 15 to 25 µm. Standard surgical masks can filter particles larger than 3 µm, while N95 respirators can filter even smaller particles. Therefore, in addition to reducing transmission of pathogens, face masks can potentially lower the burden of other inhaled airborne particles including allergens and air pollutants.

The findings of the present study demonstrated a significant reduction of both the overall burden of ragweed ocularrhinitis and all screened nasal symptoms after the adoption of anti-COVID-19 face-masking measures.
Nevertheless, despite a reduction of the pollen count in 2020, ocular symptoms showed no improvement. As suggested by Dror and collaborators, this mismatch between lower nasal symptoms and unchanged ocular symptoms is consistent with the intended function of face masks in protecting the airways from inspiratory particles, while the conjunctiva of the eye remains exposed to provoking allergens.\textsuperscript{10} Significantly, this finding is also corroborated by the fact that patients’ records on anti-allergic medications highlighted a reduction in the use of oral antihistamines and nasal sprays, while the consumption of antihistamine eye drops remained comparable to the pre-COVID-19 scenario. It is possible to surmise that other containment measures, such as work-from-home policies, may have contributed to the overall reduction of allergic symptoms. However, the isolated improvement in nasal symptoms without significant changes of ocular symptoms still underlines the beneficial role of face masks on nasal symptoms.

In conclusion, this preliminary report supports the hypothesis that massive face masks usage during the COVID-19 pandemic may have acted as an effective preventive measure in patients allergic to ragweed with severe rhinitis symptoms. Further studies on other allergens, on a larger scale and with control groups are therefore advisable and necessary in order to better investigate the pathophysiology behind face masks and personal protective equipment in allergic oculorhinitis.

**ACKNOWLEDGMENTS**
Open Access Funding provided by Universita degli Studi di Pavia within the CRUI-CARE Agreement.

**FUNDING SOURCES**
No funding was requested for the present study.

**FINANCIAL DISCLOSURES**
Nothing to disclose.

**ORCID**
Carlo Robotti MD https://orcid.org/0000-0002-2731-9754

**REFERENCES**
1. Asero R. Ragweed allergy in northern Italy: are patterns of sensitization changing? *Eur Ann Allergy Clin Immunol* 2012;44:157–159.
2. Zanon P, Chiodini E, Berra D. Allergy to ragweed in Northern Italy and prevention strategies. *Monaldi Arch Chest Dis* 2002;57(2):144-146.
3. Chen KW, Maruscia L, Tamas PT, et al. Ragweed pollen allergy: burden, characteristics, and management of an imported allergen source in Europe. *Int Arch Allergy Immunol* 2018;176(3-4):163-180.
4. Navel V, Chiambaretta F, Dutheil F. Will environmental impacts of social distancing due to the pandemic caused by SARS-CoV-2 decrease allergic disease?. *J Allergy Clin Immunol* 2020;146(1):70-71.
5. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. *Clin Exp Allergy* 1991;21(1):77-83.
6. Oberg T, Brosseau LM. Surgical mask filter and fit performance. *Am J Infect Control* 2008;36(4):276-282.
7. Lee SA, Grinshpun SA, Reponen T. Respiratory performance offered by N95 respirators and surgical masks: human subject evaluation with NaCl aerosol representing bacterial and viral particle size range. *Ann Occup Hyg* 2008;52(3):177-185.
8. Shakya KM, Noyes A, Kallin R, Peltier RE. Evaluating the efficacy of cloth facemasks in reducing particulate matter exposure. *J Expo Sci Environ Epidemiol* 2017;27(3):352-357.
9. Lee SA, Hwang DC, Li HY, et al. Particle size-selective assessment of protection of European Standard FFP respirators and surgical masks against particles-tested with human subjects. *J Healthc Eng* 2016;2016:8572493.
10. Dror AA, Eisenbach N, Marshak T, et al. Reduction of allergic rhinitis symptoms with face mask usage during the COVID-19 pandemic. *J Allergy Clin Immunol Pract* 2020;8(10):3590-3593.

**How to cite this article:** Dubini M, Robotti C, Benazzo M, Rivolta F. Impact of quarantine and face masks on ragweed-induced oculorhinits during the COVID-19 pandemic in Northern Italy. *Int Forum Allergy Rhinol*. 2022;12:220–222. https://doi.org/10.1002/alr.22889